XTL Historical Financial Ratios
| XTLB Stock | USD 2.10 0.22 11.70% |
XTL Biopharmaceutica is currently reporting on over 91 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Price To Sales Ratio of 0.15, Dividend Yield of 0.0, PTB Ratio of 2.41 or Days Sales Outstanding of 21.21 will help investors to properly organize and evaluate XTL Biopharmaceuticals financial condition quickly.
XTL |
About XTL Financial Ratios Analysis
XTL BiopharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate XTL Biopharmaceutica investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on XTL financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across XTL Biopharmaceutica history.
XTL Biopharmaceutica Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing XTL Biopharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on XTL Biopharmaceutica sales, a figure that is much harder to manipulate than other XTL Biopharmaceuticals Ltd multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Most ratios from XTL Biopharmaceutica's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into XTL Biopharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At present, XTL Biopharmaceutica's PTB Ratio is projected to increase slightly based on the last few years of reporting. The current year's Capex To Depreciation is expected to grow to 8.91, whereas Price To Sales Ratio is forecasted to decline to 0.15.
| 2023 | 2024 (projected) | Days Sales Outstanding | 22.33 | 21.21 | PTB Ratio | 2.3 | 2.41 |
XTL Biopharmaceutica fundamentals Correlations
Click cells to compare fundamentals
XTL Biopharmaceutica Account Relationship Matchups
High Positive Relationship
High Negative Relationship
XTL Biopharmaceutica fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 0.01 | 0.0251 | 0.0319 | 0.0167 | 2.3 | 2.41 | |
| Book Value Per Share | 0.0136 | 0.0122 | 0.008664 | 0.007339 | 0.004074 | 0.00387 | |
| Free Cash Flow Yield | (13.03) | (5.43) | (6.16) | (13.53) | (0.14) | (0.15) | |
| Operating Cash Flow Per Share | (0.001587) | (0.001766) | (0.001653) | (0.001704) | (0.001297) | (0.001362) | |
| Pb Ratio | 0.01 | 0.0251 | 0.0319 | 0.0167 | 2.3 | 2.41 | |
| Free Cash Flow Per Share | (0.00177) | (0.001655) | (0.001704) | (0.001653) | (0.001297) | (0.001362) | |
| Roic | (0.0978) | (0.11) | (0.12) | (0.84) | (0.3) | (0.33) | |
| Net Income Per Share | 0.005807 | (0.00262) | (0.001521) | 7.07E-4 | (0.002474) | (3.0E-6) | |
| Cash Per Share | 0.0131 | 0.0118 | 0.009954 | 0.006829 | 0.003681 | 0.003497 | |
| Pocfratio | (0.0769) | (0.18) | (0.16) | (0.0739) | (7.21) | (6.85) | |
| Pfcf Ratio | (0.0768) | (0.18) | (0.16) | (0.0739) | (7.21) | (6.85) | |
| Ev To Operating Cash Flow | 4.83 | 4.09 | 2.67 | 2.25 | (5.23) | (4.97) | |
| Pe Ratio | (0.0519) | (0.2) | 0.39 | (0.0494) | (2.9K) | (2.7K) | |
| Ev To Free Cash Flow | 4.82 | 4.08 | 2.67 | 2.25 | (5.23) | (4.97) | |
| Earnings Yield | (19.28) | (4.99) | 2.55 | (20.25) | (3.5E-4) | (3.67E-4) | |
| Intangibles To Total Assets | 0.0527 | 0.0584 | 0.0574 | 0.0908 | 0.16 | 0.18 | |
| Current Ratio | 32.39 | 29.44 | 24.1 | 20.35 | 9.93 | 7.98 | |
| Tangible Book Value Per Share | 0.0128 | 0.0114 | 0.008046 | 0.006642 | 0.003376 | 0.003208 | |
| Graham Number | 0.0283 | 0.0204 | 0.0117 | 0.0202 | 5.47E-4 | 5.2E-4 | |
| Shareholders Equity Per Share | 0.0136 | 0.0122 | 0.008664 | 0.007339 | 0.004074 | 0.00387 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (0.03) | Return On Assets (0.14) | Return On Equity (0.13) |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.